AMRX Stock Overview Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Amneal Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Amneal Pharmaceuticals Historical stock prices Current Share Price US$7.85 52 Week High US$9.48 52 Week Low US$5.01 Beta 1.1 1 Month Change -6.44% 3 Month Change -5.88% 1 Year Change 33.73% 3 Year Change 56.37% 5 Year Change 62.86% Change since IPO -47.70%
Recent News & Updates
Independent Director recently sold US$334k worth of stock Nov 26
Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Nov 22
Consensus EPS estimates fall by 17% Nov 21
Senior VP recently sold US$376k worth of stock Nov 20
Senior VP notifies of intention to sell stock Nov 17
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price Nov 10 See more updates
Independent Director recently sold US$334k worth of stock Nov 26
Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Nov 22
Consensus EPS estimates fall by 17% Nov 21
Senior VP recently sold US$376k worth of stock Nov 20
Senior VP notifies of intention to sell stock Nov 17
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price Nov 10
Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023) Nov 10
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024 Nov 08
New major risk - Shareholder dilution Nov 07
Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 09
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials Aug 20
Insider recently sold US$775k worth of stock Aug 18
Insider notifies of intention to sell stock Aug 16
Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023) Aug 11
Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024 Aug 09
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules Aug 08
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags Jul 30
Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 12
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success Jul 10
Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant Jul 10
Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar Jul 03
Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies Jun 06
Independent Director recently sold US$256k worth of stock May 21
Independent Director notifies of intention to sell stock May 19
Price target increased by 13% to US$8.25 May 06
New major risk - Negative shareholders equity May 04
First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) May 04
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose Apr 25
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA) Apr 19
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price Apr 15
Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024 Apr 11
Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024 Mar 23
Price target increased by 7.3% to US$7.31 Mar 21
Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet? Mar 19
Insider exercised options and sold US$332k worth of stock Mar 06
Full year 2023 earnings: EPS misses analyst expectations Mar 04
Consensus EPS estimates fall by 17% Mar 03
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Mar 01
Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024 Feb 01 Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry Dec 28
Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company Dec 10
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt? Nov 28
New major risk - Financial position Nov 09
Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023 Oct 24
Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 06
Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Sep 24 Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection
Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease Aug 25
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt? Aug 08
Price target increased by 50% to US$5.25 Aug 07
Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 05
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 04
Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics Jul 27
Amneal Pharmaceuticals Could Have An Upbeat Q2 Jul 10
Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023 Jul 07
Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter Jul 04
Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable Jun 15
Consensus EPS estimates fall by 25% May 26
Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States May 17
Price target decreased by 18% to US$3.50 May 09
Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023 May 06
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 06
These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively Apr 18
Price target decreased by 18% to US$4.20 Mar 10
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 03
Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023 Feb 01
Amneal Pharmaceuticals: Risk Still Persists Jan 23
Amneal Pharma reaffirms 2022 guidance Jan 10
Amneal joins hands with Orion to commercialize generic products in Europe and more countries Jan 04
Insufficient new directors Jan 01
Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval Dec 21
Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load Dec 20
Amneal Pharmaceuticals large shareholder TPG cuts stake Dec 14
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States Nov 23
Price target decreased to US$5.10 Nov 16
Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease Nov 12
FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203 Nov 11
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 05 Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022
Amneal Pharmaceuticals Q3 2022 Earnings Preview Nov 03
Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection Nov 03
Amneal Pharmaceuticals, Inc. Announces Management Changes Nov 01
Amneal Pharmaceuticals: A Small 'Thumbs Up' Oct 28
Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022 Oct 07
Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS Oct 04
Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty Sep 07
Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease Sep 01
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet Sep 01
Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment Aug 31
Consensus forecasts updated Aug 22
Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose Aug 12
Price target decreased to US$5.80 Aug 08
Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022 Aug 06 Shareholder Returns AMRX US Pharmaceuticals US Market 7D -2.7% 1.6% -2.2% 1Y 33.7% 9.7% 23.9%
See full shareholder returns
Return vs Market: AMRX exceeded the US Market which returned 23.9% over the past year.
Price Volatility Is AMRX's price volatile compared to industry and market? AMRX volatility AMRX Average Weekly Movement 4.7% Pharmaceuticals Industry Average Movement 10.4% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: AMRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMRX's weekly volatility (5%) has been stable over the past year.
About the Company Founded Employees CEO Website 2002 7,850 Chirag Patel amneal.com
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Show more Amneal Pharmaceuticals, Inc. Fundamentals Summary How do Amneal Pharmaceuticals's earnings and revenue compare to its market cap? AMRX fundamental statistics Market cap US$2.43b Earnings (TTM ) -US$184.45m Revenue (TTM ) US$2.68b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AMRX income statement (TTM ) Revenue US$2.68b Cost of Revenue US$1.70b Gross Profit US$979.05m Other Expenses US$1.16b Earnings -US$184.45m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.60 Gross Margin 36.53% Net Profit Margin -6.88% Debt/Equity Ratio -7,524.6%
How did AMRX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 22:32 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Balaji Prasad Barclays Balaji Prasad Barclays Gary Nachman BMO Capital Markets Equity Research
Show 17 more analysts 
